CD44 and breast cancer: Consistently, CSCs, isolated using CD44+/CD24−/low from human breast cancer, demonstrated resistance against the chemotherapeutic agents and the proportion of CD44+/CD24−/low cells increased in breast cancer patients after treatment with anticancer drugs, including docetaxel, doxorubicin, and cyclophosphamide [80].